FDA New Drug and Biologic Approvals, 2018 Midyear Review

Mary L Windle, PharmD

Disclosures

August 01, 2018

In This Article

Urinary Tract Infection: Zemdri (plazomicin)

Indication: Indicated for complicated urinary tract infections (cUTIs) in adults, including pyelonephritis caused by the following susceptible microorganism(s): E coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.

Mechanism: Aminoglycoside antibiotic that has been engineered to overcome aminoglycoside-modifying enzymes, the most common aminoglycoside-resistance mechanism in Enterobacteriaceae, and has in vitro activity against extended-spectrum beta-lactamase-producing, aminoglycoside-resistant, and carbapenem-resistant isolates.

Dosage: 15 mg/kg IV every 24 hr for up to 7 days.

Approval was based on the phase 3 evaluating plazomicin in cUTI (EPIC) clinical trial (N=388). Plazomicin was noninferior compared with meropenem for clinical cure and microbiologic eradication at day 5 and test-of-cure at about day 17.

Reference:

  • Cloutier DJ, Miller LG, Komirenko AS, et al. Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study. Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 22-25, 2017.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....